A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

AIMS: The 24‐week, prospective, randomized, double‐blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). METHODS: Patients had probable AD and Mini–Mental State Examination scores ≥3...

Descripción completa

Detalles Bibliográficos
Autores principales: Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233957/
https://www.ncbi.nlm.nih.gov/pubmed/23924050
http://dx.doi.org/10.1111/cns.12158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233957/
https://www.ncbi.nlm.nih.gov/pubmed/23924050
http://dx.doi.org/10.1111/cns.12158

Ejemplares similares